Cumberland Pharmaceuticals Inc.
US ˙ NasdaqGS ˙ US2307701092

SecurityCPIX / Cumberland Pharmaceuticals Inc.
InstitutionDimensional Fund Advisors Lp
Latest Disclosed Ownership652,561 shares
Ownership 4.40%
Dimensional Fund Advisors Lp ownership in CPIX / Cumberland Pharmaceuticals Inc.

2022-02-08 - Dimensional Fund Advisors Lp has filed an SC 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 652,561 shares of Cumberland Pharmaceuticals Inc. (US:CPIX). This represents 4.4 percent ownership of the company. In their previous filing dated 2021-02-12 , Dimensional Fund Advisors Lp had reported owning 781,891 shares, indicating a decrease of -16.54 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date
Effective
Date
Form Prev
Shares
Latest
Shares
ΔShares
(Percent)
Ownership
(Percent)
ΔOwnership
(Percent)
2022-02-08 2022-02-08 13G/A 781,891 652,561 -16.54 4.40 -15.38
2021-02-12 2021-02-12 13G/A 860,319 781,891 -9.12 5.20 -8.29
2020-02-12 2020-02-12 13G/A 880,248 860,319 -2.26 5.67 0.00
2019-02-08 2019-02-08 13G/A 888,411 880,248 -0.92 5.67 0.53
2018-02-09 2018-02-09 13G/A 852,976 888,411 4.15 5.64 7.02
2017-02-09 2017-02-09 13G 853,836 852,976 -0.10 5.27 1.54
2016-02-09 2016-02-09 13G 853,836 5.19

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-07 2026-03-31 13F CUMBERLAND PHARMACEUTICALS I COM 230770109 276,359 4,081 1.50 898 -17.08 0.0000
2026-02-12 2025-12-31 13F CUMBERLAND PHARMACEUTICALS I COM 230770109 272,278 -8,591 -3.06 1,084 23.63 0.0002
2025-11-12 2025-09-30 13F CUMBERLAND PHARMACEUTICALS I COM 230770109 280,869 27,980 11.06 876 3.42 0.0002
2025-08-12 2025-06-30 13F CUMBERLAND PHARMACEUTICALS I COM 230770109 252,889 700 0.28 847 -20.54 0.0002
2025-05-13 2025-03-31 13F CUMBERLAND PHARMACEUTICALS I COM 230770109 252,189 -20,780 -7.61 1,067 65.02 0.0003
2025-02-13 2024-12-31 13F CUMBERLAND PHARMACEUTICALS I COM 230770109 272,969 -11,036 -3.89 647 77.96 0.0002
2024-11-07 2024-09-30 13F CUMBERLAND PHARMACEUTICALS I COM 230770109 284,005 -20,104 -6.61 364 -21.94 0.0001
2024-08-09 2024-06-30 13F CUMBERLAND PHARMACEUTICALS I COM 230770109 304,109 -53,506 -14.96 465 -22.50 0.0001
2024-05-10 2024-03-31 13F CUMBERLAND PHARMACEUTICALS I COM 230770109 357,615 -8,319 -2.27 601 -5.66 0.0002
2024-02-07 2023-12-31 13F CUMBERLAND PHARMACEUTICALS I COM 230770109 365,934 -13,786 -3.63 637 -11.30 0.0002
2023-11-09 2023-09-30 13F CUMBERLAND PHARMACEUTICALS I COM 230770109 379,720 -127,570 -25.15 718 -3.76 0.0002
2023-08-09 2023-06-30 13F CUMBERLAND PHARMACEUTICALS I COM 230770109 507,290 -101,743 -16.71 746 -37.24 0.0002
2023-05-12 2023-03-31 13F CUMBERLAND PHARMACEUTICALS I COM 230770109 609,033 -14,838 -2.38 1,188 118,600.00 0.0004
2023-02-09 2022-12-31 13F CUMBERLAND PHARMACEUTICALS I COM 230770109 623,871 4 0.00 1 -99.93 0.0004
2022-11-10 2022-09-30 13F CUMBERLAND PHARMACEUTICALS I COM 230770109 623,867 -3,333 -0.53 1,503 15.44 0.0006
2022-08-12 2022-06-30 13F CUMBERLAND PHARMACEUTICALS I COM 230770109 627,200 -6,704 -1.06 1,302 -27.18 0.0005
2022-05-13 2022-03-31 13F CUMBERLAND PHARMACEUTICALS I COM 230770109 633,904 -18,657 -2.86 1,788 -41.32 0.0006
2022-02-09 2021-12-31 13F CUMBERLAND PHARMACEUTICALS I COM 230770109 652,561 -44,093 -6.33 3,047 61.99 0.0009
2021-11-12 2021-09-30 13F CUMBERLAND PHARMACEUTICALS I COM 230770109 696,654 -58,846 -7.79 1,881 -12.47 0.0006
2021-08-12 2021-06-30 13F CUMBERLAND PHARMACEUTICALS I COM 230770109 755,500 17,619 2.39 2,149 -3.89 0.0007
2021-05-14 2021-03-31 13F CUMBERLAND PHARMACEUTICALS I COM 230770109 737,881 -44,010 -5.63 2,236 -2.74 0.0007
2021-03-08 2020-12-31 13F/A-2 CUMBERLAND PHARMACEUTICALS I COM 230770109 781,891 -17,063 -2.14 2,299 -10.37 0.0008
2021-02-11 2020-12-31 13F CUMBERLAND PHARMACEUTICALS I COM 230770109 781,891 -17,063 2,299 830.2766
2020-11-12 2020-09-30 13F CUMBERLAND PHARMACEUTICALS I COM 230770109 798,954 -31,733 -3.82 2,565 -7.27 0.0011
2020-08-13 2020-06-30 13F CUMBERLAND PHARMACEUTICALS I COM 230770109 830,687 -21,935 -2.57 2,766 -10.63 0.0012
2020-05-14 2020-03-31 13F CUMBERLAND PHARMACEUTICALS I COM 230770109 852,622 -7,697 -0.89 3,095 -30.15 0.0016
2020-02-14 2019-12-31 13F CUMBERLAND PHARMACEUTICALS I COM 230770109 860,319 231 0.03 4,431 -13.12 0.0016
2019-11-12 2019-09-30 13F CUMBERLAND PHARMACEUTICALS I COM 230770109 860,088 -2,831 -0.33 5,100 -7.22 0.0020
2019-08-13 2019-06-30 13F CUMBERLAND PHARMACEUTICALS I COM 230770109 862,919 -13,320 -1.52 5,497 7.97 0.0021
2019-08-12 2019-03-31 13F/A-2 CUMBERLAND PHARMACEUTICALS I COM 230770109 876,239 -4,009 -0.46 5,091 -8.20 0.0020
2019-05-10 2019-03-31 13F CUMBERLAND PHARMACEUTICALS I COM 230770109 876,239 -4,009 5,091
2019-02-26 2018-12-31 13F/A-1 CUMBERLAND PHARMACEUTICALS I COM 230770109 880,248 1,900 0.22 5,546 10.59 0.0025
2019-02-13 2018-12-31 13F CUMBERLAND PHARMACEUTICALS I COM 230770109 880,248 1,900 5,546
2018-11-13 2018-09-30 13F CUMBERLAND PHARMACEUTICALS I COM 230770109 878,348 5,674 0.65 5,015 -6.24 0.0019
2018-08-10 2018-06-30 13F CUMBERLAND PHARMACEUTICALS I COM 230770109 872,674 -10,411 -1.18 5,349 -9.32 0.0021
2018-05-11 2018-03-31 13F CUMBERLAND PHARMACEUTICALS I COM 230770109 883,085 -5,326 -0.60 5,899 -10.51 0.0025
2018-02-12 2017-12-31 13F CUMBERLAND PHARMACEUTICALS I COM 230770109 888,411 16,324 1.87 6,592 7.07 0.0027
2017-11-13 2017-09-30 13F CUMBERLAND PHARMACEUTICALS I COM 230770109 872,087 5,804 0.67 6,157 0.52 0.0027
2017-08-11 2017-06-30 13F CUMBERLAND PHARMACEUTICALS I COM 230770109 866,283 2,464 0.29 6,125 2.17 0.0028
2017-05-12 2017-03-31 13F CUMBERLAND PHARMACEUTICALS I COM 230770109 863,819 10,843 1.27 5,995 27.80 0.0029
2017-02-09 2016-12-31 13F CUMBERLAND PHARMACEUTICALS I COM 230770109 852,976 2,791 0.33 4,691 10.14 0.0023
2016-11-10 2016-09-30 13F CUMBERLAND PHARMACEUTICALS I COM 230770109 850,185 -322 -0.04 4,259 11.29 0.0023
2016-08-09 2016-06-30 13F CUMBERLAND PHARMACEUTICALS I COM 230770109 850,507 -2,004 -0.24 3,827 -0.03 0.0022
2016-05-13 2016-03-31 13F CUMBERLAND PHARMACEUTICALS I COM 230770109 852,511 -1,325 -0.16 3,828 -14.76 0.0023
2016-02-10 2015-12-31 13F CUMBERLAND PHARMACEUTICALS I COM 230770109 853,836 1,872 0.22 4,491 -8.65 0.0028
2015-11-13 2015-09-30 13F CUMBERLAND PHARMACEUTICALS I COM 230770109 851,964 -1,683 -0.20 4,916 -19.46 0.0032
2015-08-14 2015-06-30 13F CUMBERLAND PHARMACEUTICALS I COM 230770109 853,647 6,512 0.77 6,104 8.19 0.0037
2015-05-14 2015-03-31 13F CUMBERLAND PHARMACEUTICALS I COM 230770109 847,135 -2,551 -0.30 5,642 10.67 0.0036
2015-02-06 2014-12-31 13F CUMBERLAND PHARMACEUTICALS I COM 230770109 849,686 847 0.10 5,098 21.58 0.0033
2014-11-13 2014-09-30 13F CUMBERLAND PHARMACEUTICALS I COM 230770109 848,839 -7,742 -0.90 4,193 8.77 0.0030
2014-08-08 2014-06-30 13F CUMBERLAND PHARMACEUTICALS I COM 230770109 856,581 123,202 16.80 3,855 16.82 0.0027
2014-05-14 2014-03-31 13F CUMBERLAND PHARMACEUTICALS I COM 230770109 733,379 4,373 0.60 3,300 -11.41 0.0025
2014-02-12 2013-12-31 13F CUMBERLAND PHARMACEUTICALS I COM 230770109 729,006 -7,403 -1.01 3,725 11.66 0.0029
2013-11-13 2013-09-30 13F CUMBERLAND PHARMACEUTICALS I COM 230770109 736,409 -1,285 -0.17 3,336 -11.51 0.0029
2013-08-15 2013-06-30 13F CUMBERLAND PHARMACEUTICALS I COM 230770109 737,694 737,694 3,770 0.0036
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.